Antegenes develops and implements advanced genetic tests based on polygenic risk score technology to assess individual cancer risk and provide clinical recommendations for personalised prevention. Its tests currently evaluate genetic risk for breast cancer, prostate cancer, colon cancer and skin melanoma. The company positions its offerings to enable more accurate prevention and earlier detection measures. Founded in 2018 in Estonia, Antegenes has expanded operations beyond Estonia and the U.K. into Sweden, Norway, Portugal and Spain and plans to enter Germany in the coming months. The company has raised €2.3 million in funding to scale its tests and expand into new markets. Antegenes develops genetic tests that use polygenic risk score technology to assess an individual’s predisposition to cancer and include clinical recommendations for personalised prevention and early detection. Its tests currently evaluate risk for breast cancer, prostate cancer, colon cancer and skin melanoma and provide three actionable data points: absolute 10‑year risk, comparison to the general population of the same age, and relative risk versus the general population. The company’s offering is delivered via a five‑minute saliva test and aims to make genetic risk assessment more accessible and affordable. Products are based on peer‑reviewed international research and have been evaluated and validated using anonymous population data from the Estonian Biobank and UK Biobank. Antegenes has raised €500k and signed a long‑term strategic partnership with UK distributor Everything Genetic Ltd to expand implementation into the UK healthcare system and further develop personalised cancer prevention methods.

Total raised

$3M

Funding rounds

2

Latest round

Seed

Latest activity

Aug 2022